← SynDRA
I-BET-151
SynDRA canonical compound SYN0062532 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | BRD2 | BRD3 | BRD4 |
|---|
| Mechanism of action | bromodomain inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- BET bromodomain inhibitor
- BRD4 INHIBITOR
- BRD2 INHIBITOR
- BRD3 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- EGFR
- MAP3K8
- HDAC6
- MAPKAPK2
- SRC
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- COMT
- CP2C9
- CP2D6
- CP3A7
- GAMT
- GNMT
- GPX1
- HNMT
- KSYK
- NNMT
- NSD2
- NTM1A
- NTMT1
- PNMT
- SYK
- TP53
Cross-references
Synonyms
- GSK 1210151A (I-BET151)
- GSK-1210151A
- GSK1210151A
- I-BET151
- I-BET151 (GSK1210151A)
- I-Bet151
- RefChem:545060
- MFCD22124472
- GSK1210151A (I-BET151)
- 3zyu
- 4alg
- VUVUVNZRUGEAHB-CYBMUJFWSA-N
- C23H21N5O3
- 1GH
- MLS006011182
- GTPL7518
- SCHEMBL1906755
- SCHEMBL29366680
- SCHEMBL29376121
- CHEBI:95083
- I-BET151?
- EX-A1561
- BDBM50380682
- NSC767599
- s2780
- AKOS016004407
- CS-0930
- FD43075
- NSC-767599
- NCGC00344588-01
- NCGC00344588-04
- NCGC00344588-08
- NCGC00344588-15
- NCGC00344588-16
- NCGC00344588-17
- AC-27406
- HY-13235
- SMR004702951
- SW219264-1
Look up I-BET-151 in the interactive SynDRA portal →